NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Showcase your company news with guaranteed exposure both in print and online 25 years ago, Denver's economy thrived on IT, real estate & oil. DBJ will kick… Be Inspired! Meet Your Mentor! Make ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 12, 2025. REUTERS/Brendan McDermid/File Photo The S&P 500 advanced on Thursday, with gains in ...

After hours: February 10 at 6:46:55 PM EST ...

Pre-market: 6:09:50 am GMT-5 ...